Gilead: Downgrade To 'Hold' Rating Despite Arcellx Acquisition

Gilead Sciences, Inc. is downgraded to Hold due to uncertainty on the Arcellx acquisition and cell therapy portfolio challenges. Read more on GILD stock here.